The clinical course of chronic myeloid leukaemia (CML) is characterised by a chronic phase followed by an acute phase or blast crisis. Lymphoid transformation accounts for 20-30% of such events, with the majority of cases being of B cell origin. Extramedullary transformation occurs in approximately 10% of cases. We report a case of T cell lymphoblastic transformation in CML presenting as an extramedullary mass after allogeneic stem cell transplant. This case supports the growing evidence that CML arises in the pluripotent stem cell. Keywords: chronic myeloid leukaemia; T lymphoblastic transformation; interleukin-2; allogeneic bone marrow transplantation; donor lymphocyte infusion Chronic myeloid leukaemia (CML) is a clonal disorder of haemopoiesis characterised by the Philadelphia chromosome (t(9;22)(q34;q11), Ph).
/l and the peripheral blood was consistent with a diagnosis of CML. Conventional cytogenetic analysis confirmed the presence of the t(9;22)(q34;q11) Philadelphia chromosome with no other cytogenetic abnormality. He was initially managed by leucapheresis and hydroxyurea. ␣-Interferon (IFN␣) was added later. He did not have a major cytogenetic response to IFN␣.
In October 1996 he underwent an allogeneic bone marrow transplant from an HLA-matched male sibling donor. He received busulphan 4 mg/kg p.o. in divided doses daily for 4 days (total 16 mg/kg) and cyclophosphamide 60 mg/kg once daily i.v. on days 1 and 2 (total 120 mg/kg) as conditioning regimen and cyclosporin A and methotrexate (10 mg/m 2 on days 1, 3 and 6) as graft-versus-host disease (GVHD) prophylaxis. The peri-transplant period was uneventful except for the development of haemorrhagic cystitis. He did not develop any significant acute GVHD. His neutrophil count reached 0.5 × 10 He presented 5 months after the second transplant with a painful swelling on the left anterior chest. Computed tomography showed this to be a large homogenous soft tissue mass extending between and involving the left pectoral muscles and causing destruction of the second rib with extension into the pleural. A trucut biopsy of this mass (Figure 1a) showed it to consist of lymphoblasts of T cell phenotype which were CD3 + , MT1 + , UCHL-1 + (Figure 1b) . Staining for B cell markers (CD20 and CD79a), myeloid markers (CD15, NP57), an epithelial marker (AE1-AE3), CD30 and Epstein-Barr virus LMP-1 were all negative. FISH analysis showed the presence of two copies of the bcr-abl fusion gene in 60% of these cells and one copy in 26% (Figure 1c ). Conventional cytogenetics demonstrated additional complex abnormalities (50, XY, t(1;3)(p31;q26), +8, t(9;22)(q34;q11), +19 , +21, der(22)t(9;22)(q34;q11) [11] /50, idem, add(14)(q32) [2] / 46, XY [6] ). Bone marrow morphology and immunophenotyping did not show any T lymphoblasts or excess myeloblasts, but cytogenetics showed the presence of cells with similar abnormalities in the bone marrow (50, XY, t(1;3)(p31;q26), +8, t(9;22)(q34;q11), +19, +21, der (22)t(9;22)(q34;q11) [2] /50, XY, idem, add(14)(q32) [5] /50, XY, idem, add(2)(q?) [1] /46, XY [2] ).
Discussion
The majority of blast transformations in CML are myeloid in origin, with lymphoid transformation accounting for approximately 20% of cases. 3 However, T cell transformation is rare. Extramedullary transformation occurs in 10-16% of cases of CML, [4] [5] [6] most frequently in the lymph nodes. 6, 7 Extramedullary T transformation occurring outside the lymphoreticular system is even rarer. Two such cases are reported among 235 patients with CML. 4 In this report, we describe a third case of T lymphoblastic transformation outside the haemopoietic and lymphoreticular systems.
In this case immunophenotypic studies of the mass demonstrated the T cell lineage of the cells. There was no immunophenotypic evidence of T cell infiltrate in the bone marrow. Several studies have previously shown that the bone marrow may not be involved at the onset of extramedullary transformation, [6] [7] [8] although this may occur later in the disease. 9, 10 Of interest are the cytogenetic findings. The T lymphoblasts exhibited complex cytogenetic abnormalities appearing to have arisen from the malignant clone which initially had progressed to a myeloid blast crisis. This is in keeping with recent evidence supporting the concept that T cells are part of the malignant clone. 11, 12 Treatment of the myeloid blast crisis with a combination of donor lymphocytes and IL-2 infusions resulted in the decline in the number of myeloblasts. A recent paper reports the use of donor lymphocyte infusions in relapsed CML, with response in 13 out of 18 patients and an overall survival of 52% at 5 years. 13 Significant GVHD was reported with higher T cell doses (Ͼ1 × 10 8 /kg). In a recent report of eight cases of CML 14 (four chronic phase, two accelerated phase, two blast crisis) treated with donor lymphocyte infusion either alone or in combination with other immunotherapy, no response was seen to donor lymphocyte infusion in blast crisis following allogeneic bone marrow transplant, although four out of four patients in chronic phase responded in keeping with previously published results. 15 GVHD was seen in 53% of cases overall and was associated with better outcome.
There is growing evidence that the use of donor lymphocyte infusion or G-CSF-mobilised peripheral blood stem cells may increase extramedullary relapse. [16] [17] [18] [19] Addition of IL-2 has been associated with increased response rates 20 
while CD8
+ depletion does not appear to adversely affect outcome. 21, 22 In the current case, donor lymphocyte infusion and IL-2 treatment was shortly followed by the extramedullary T lymphoblastic tumour development. It remains speculative as to the role, if any, of IL-2 in this transformation.
